The pathway of gluconeogenesis is activated in liver shortly after birth and is controlled by glucagon and glucocorticoids, which stimulate, and insulin, which inhibits, the expression of genes coding for gluconeogenic enzymes.
To understand the molecular basis of this cell type-specific and coordinate control, we analyzed the c&regulatory elements of the tyrosine aminotransferase gene, which confer liver cell-specific expression in dependence of these hormones. The CAMP-responsive element (CRE) of the TAT gene is an essential element within a liverspecific enhancer and is recognized by the CREbinding protein (CREB) in a phosphorylation-dependent manner. The glucocorticoid response is mediated by a complex regulatory unit comprised of the glucocorticoid receptor and other transcription factor-binding sites. Here, we show that both the CAMP-and glucocotticoid-inducible enhancers are targets for the antagonistic effects of insulin. The insulin-responsive sequences coincide with the CREB-binding site of the CAMP-responsive enhancer and a hepatocyte nuclear factor-3-binding site within the glucocorticoid-responsive unit. This design of the hormone-dependent enhancers reflects the molecular mechanism underlying the onset of tyrosine aminotransferase expression at birth when insulin levels decrease and concentrations of glucagon and glucocorticoids increase. (Molecular Endocrinology 8: 895-903, 1994) INTRODUCTION Hepatic glucose metabolism is a highly controlled process, catalyzed by a variety of liver-specific enzymes (1). The onset of gluconeogenesis occurs around the time of birth, when expression of gluconeogenic enzymes is first detected (2). Enzyme synthesis and activity are controlled by blood glucose levels and are subject to complex regulatory mechanisms involving hormonal and tissue-specific signals. Genes encoding gluconeogenie enzymes such as phosphoenolpyruvate caboxykinase (PEPCK) and tyrosine aminotransferase (TAT) are transcriptionally up-regulated by glucagon, which acts via the CAMP pathway, and glucocorticoids, whereas insulin negatively affects gene transcription (3-7). The regulatory sequences mediating CAMP and glucocorticoid responses have been studied in detail for both the PEPCK and TAT genes. Glucocorticoid regulation of the PEPCK gene requires a composite glucocorticoid response unit (GRU) positioned at -400 basepairs (bp), whereas a CAMP-responsive element (CRE) is located around -90 bp (8). In the TAT gene, a glucocorticoid-inducible enhancer at -2.5 kilobases (kb) has been identified which is composed of a glucocorticoid-responsive element (GRE) and transcription factorbinding sites, including a binding site for hepatocyte nuclear factor-3 (HNF3) (9-11). The CRE of the TAT gene is located at -3.6 kb (12, 13) and is flanked by a HNF-Cbinding site (11). It has been demonstrated that the two liver-enriched transcription factors HNF3 and HNF4 interact with the hormone-responsive enhancers to restrict TAT promoter activity to liver cells (11).
Glucocorticoids interact directly with their intracellular receptor, thereby inducing DNA binding of the hormonereceptor complex (14). In contrast, many growth factors and peptide hormones, e.g. glucagon, bind to receptors on the cell surface and activate transcription of target genes via second messengers, such as CAMP. Increased intracellular CAMP levels lead to the activation of CAMP-dependent protein kinase-A (PKA), which phoshorylates a variety of nuclear transcription factors (4, 25, 26) . Despite functional glucocorticoid receptor and high levels of circulating steroid hormones before birth, TAT expression in fetal liver is not induced, due to high insulin concentrations in the uterus (7).
The results presented here elucidate the underlying molecular mechanism of the inhibitory effect of insulin on glucocorticoidand CAMP-induced transcription. In a detailed analysis of both inducible enhancer elements within the TAT 5'-regulatory region, we identified the responsive sequences for insulin action as binding sites for CREB and members of the HNF3 family.
RESULTS
The CAMP-Dependent Enhancer Is a Target for Insulin Repression of TAT Gene Transcription
Tyrosine aminotransferase gene transcription is controlled by three enhancers within the 5'-flanking region (11, 27) . A liver-specific enhancer is located at -11 kb (27) . A CAMP-responsive element (12, 13) and a glucocorticoid-dependent enhancer (9) have been identified at positions -3.6 and -2.5 kb, respectively. To investigate the mechanism and define the c&regulatory sequence(s) through which insulin antagonizes CAMPinduced transcription, we stably introduced fusion genes containing TAT 5'-flanking sequences fused to the bacterial chloramphenicol acetyltransferase (CAT) gene into the well differentiated FTO-2B hepatoma cells. The constructs pTATCAT-11 .l and pTATCAT-11.1/A-3.6 (Fig. 1A) transcription by nuclear run-on analysis (Fig. 1 B) . Insulin treatment of cells stably transfected with pTATCAT-11 .l almost completely blocked the activation of CAT gene transcription by forskolin. A very similar pattern was observed for the endogenous TAT and PEPCK genes (Fig. IB) . In contrast, no significant effect of insulin on transcription was observed for the pTATCAT-11.1/A-3.6 construct. A quantification of the nuclear run-on analysis is shown in Fig. 1C . The data demonstrate that the enhancer at -3.6 kb is essential for the negative effect of insulin on CAMP-induced TAT gene transcription.
The CRE within the -3.6-kb Enhancer Mediates Repression of Induced TAT Gene Transcription by Insulin
The -3.6-kb enhancer consists of a CRE in combination with a binding site for 12, 13) . To define the target for the observed insulin repression, FTO-2B cells were stably transfected with the constructs pTATCAT-3675, including both elements, and pTATCAT-3628, in which the CRE is deleted but the HNF4-binding site is retained (13). The effects of insulin on TATCAT mRNA synthesis were examined by ribonuclease protection assays. Treatment of FTO-2B cells with insulin did not affect transcription of the endogenous albumin gene, which, therefore, was used as an internal control. As shown in Fig. 2 , the -3675 TATCAT construct displays a response very similar to that observed with pTATCAT-11 .l or the endogenous TAT gene shown in Fig. 1 . Deletion of only the CRE, however, not only abolished CAMP induction (13) but also resulted in a complete loss of the insulin repression. To test directly whether the TATCRE mediates repression by insulin, we concatemerized this DNA sequence (-3659 to -3634) and inserted it up-stream of the herpes simplex virus thymidine kinase (TK) promoter. As a control, we used DNA that differs from the original sequence by only a triple-Point mutation (13). Both constructs were stably transfected into FTO-2B hepatoma cells and analyzed by ribonuclease protection experiments. The concatemerized TATCRE, but not the mutated version (MUTCRE), confers CAMP responsiveness to the TK promoter ( Fig. 3A) (13). In the presence of insulin, CAMP induction of the TATCRE is strongly repressed, whereas the mutated CREs do not show any insulin effect (Fig. 3B) . From the nuclear run-on and ribonuclease protection experiments, we conclude that the CRE mediates the negative effect of insulin on CAMP-induced TAT gene transcription.
Using concatemerized PEPCKCREs (-96 to -77) up-stream of the TK promoter, we also observed repression of the reporter gene by insulin similar to the effects on the TATCRE construct ( Fig. 3) suggesting that the CREs of both the TAT and PEPCK gene are capable of mediating the antagonistic effects of insulin and CAMP on transcription. Deletion of the TATCRE Abolishes Insulin Repression Different TAT 5'-flanking sequences extending to -3675 and -3628 bp, respectively, were cloned in front of the CAT gene. Stably transfected pools of FTO-PB hepatoma cells were treated for 4 h, as described in Fig. 1 , and expression was analyzed in a ribonuclease protection experiment. The autoradiograph shown for the pTATCAT-3675 construct was exposed overnight, whereas the autoradiograph for pTATCAT-3628 was exposed for 3 days to compensate for the reduced signals. Transfected constructs are shown below; symbols are as detailed in Fig. 1 Fig. 3 . The CRE Is the Target for the Negative Effect of Insulin on CAMP-Induced TAT and PEPCK Gene Transcription A, The TATCRE and the PEPCKCRE confer insulin responsiveness to a heterologous promoter. Oligodeoxynucleotides (six direct repeats) harboring either the wild-type (TATCRE and PEPCKCRE) or the mutated version of the CRE of the TAT gene (MUTCRE) were cloned in front of the TK promoter driving the CAT gene. Stably transfected pools were treated and analyzed as described above. The autoradicgraphs shown for the TATCRE and PEPCKCRE constructs were exposed overnight, whereas the autoradiograph for the MUTCRE construct was exposed for 3 days to compensate for the reduced signals. The constructs are shown schematically below. TKCAT, 210-Nucleotide (nt) long fragment indicating transcripts correctly initiated from the TK promoter. B, Accumulation of mRNA from the CRE constructs was quantified using a Phosphorlmager (Molecular Dynamics, Sunnyvale, CA) and corrected for the albumin control. The results shown represent three independent experiments for each construct, with SDS indicated. Quantification of the MUTCRE construct was corrected for the 6 times longer exposure. gene transcription requires dephosphorylation on Ser'33, which is mediated by Ser/Thr-phosphatase type 1 or type 2 (20, 31, 32). As insulin antagonizes CAMPinduced TAT gene expression, we wished to know whether decreased phosphorylation of Ser'33 could be the result of insulin action. Therefore, we preformed Western blot analysis using an antipeptide antiserum that recognizes CREB (amino acids 123-136) only when phosphorylated at Ser'33 (33). Crude nuclear extracts were prepared form FTO-2B cells after 15-min hormone induction and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). As expected, a band corresponding to phosphorylated CREB appears only after forskolin treatment on a Western blot, whereas in unstimulated cells, no phosphorylated CREB is detectable (Fig. 4A) . Insulin treatment does not reduce CAMP-induced phosphorylation at Ser'33. Figure 48 shows staining with anti- CREB antiserum to control loading of equal amounts of cell extract. This result indicates that Se? of CREB is not the target for the CAMP/insulin antagonism.
The polypeptide including the PKA site is entirely conserved between CREB and ATF-1. Therefore, the phosphorylation state of a second protein comigrating with in vitro labeled ATF-1 (34) can also be monitored on the blot by the antiphospho-CREB antiserum (Fig.  4A) . This protein shows an insulin-dependent increase in phosphorylation, and simultaneous treatment with forskolin and insulin has an additive effect on the phosphorylation level.
Glucocorticoid-Induced
TAT Gene Transcription Is Reduced by Insulin Insulin-mediated inhibition of glucocorticoid-induced TAT gene transcription has been implicated in preventing perinatal activation of the TAT gene in the uterus (7) as well as in fetal hepatocytes and hepatoma cells (25, 35) . To study the molecular mechanism of these effects, we extended our analysis to a construct that has 3.6-kb TAT regulatory sequences with a mutated nonfunctional CRE cloned in front of a CAT reporter (Fig. 5A, -3675 and treated as described above. Expression of reporter constructs was analyzed by ribonuclease protection. TKLacZ, 260-Nucleotide long fragment indicating correctly initiated transcripts from the chimeric constructs. All experiments were repeated at least three times. mains intact and strongly induces transcription in response to the synthetic glucocorticoid dexamethasone (Fig. 5A) . Treatment with insulin greatly reduces the dexamethasone-stimulated
transcription. These results demonstrate that a second target sequence for insulin action mediates the glucocorticoid/insulin antagonism.
Insulin Action Does not Impair Glucocorticoid Receptor Function
The glucocorticoid-inducible enhancer of the TAT gene is located 2.5 kb up-stream of the transcriptional start Vol8 No. 7 900 site (9). It has been demonstrated that the glucocorticoid receptor acts synergistically with adjacent transcription factors to confer hormone inducibility to the TAT gene (10, 11, 36) . Within the -2.5kb enhancer, CACCC box and CCAAT box motifs as well as a HNF-3-binding site are located next to a glucocorticoidresponsive sequence (10,ll).
In analogy to the CAMP/ insulin antagonism, where both signal transduction pathways converge at the CRE, we asked whether insulin requires the GRE for its inhibitory effect on glucocorticoid-induced transcription.
A well established mechanism describes repression of glucocor-ticoid receptor-mediated transcriptional activation by AP-1 (37, 38). As c-jun and c-fos mRNA levels are up-regulated in FTO-26 cells after insulin treatment (Reik, A., unpublished), we considered the possibility that the glucocorticoid receptor is a direct target for insulin repression. A chimeric construct composed of the (Yfetoprotein (aFP) enhancers, two GREs (39), the TATA box of the TK promoter, and the P-galactosidase (IacZ) gene as a reporter (Fig. 4B , GRE GRE) was transfected into FTO-2B cells. The aFP enhancers alone respond to neither dexamethasone nor insulin, which has been confirmed in transient and stable transfection experiments with a chimeric construct where the GRE dimer was replaced by a SPl dimer. However, the aFP enhancers are required for efficient expression of stably integrated GRE reporter constructs (data not shown). Stably transfected FTO-28 cells were induced with hormones, as indicated, and examined by ribonuclease protection analysis. The basal level of the reporter mRNA was low, whereas dexamethasone treatment leads to a dramatic increase. Insulin, however, has no effect on dexamethasone-induced mRNA levels (Fig.  5B, upper left panel) . Therefore, we conclude that insulin does not interfere with glucocorticoid receptor activity to reduce hormone-stimulated transcription.
A HNF3-Binding Site within the GRU Harbors the Target Sequence for Insulin Antagonism of Glucocorticoid Induction
To define the target sequence for insulin action, we further dissected the glucocorticoid-inducible enhancer at -2.5 kb. A minimal GRE sequence was combined with an HNF-3-binding site, a CCAAT box, or a CACCC box motif in reporter constructs (GRE HNF-3, CCAAT GRE, and CACCC GRE; Fig. 5B ), respectively.
Ribonuclease protection analysis of stably transfected FTO-28 hepatoma cells shows increased basal level activity when a GRE is combined with a transcription factorbinding site compared to a GRE dimer. Dexamethasone induction results in a 3-to 5-fold increase in mRNA levels. Insulin treatment of FTO-2B cells transfected with a CCAAT box/GRE or a CACCC box/GRE construct has no influence on induced mRNA levels. A construct consisting of the binding site for HNF-3 in combination with a GRE shows reduction of glucocorticoid-induced mRNA levels after insulin treatment, similar to the pattern obtained with the -3.6-kb TAT promoter construct (Fig. 5A, -3675 
MUTCRE). This result was confirmed in five independent
experiments. The data demonstrate that the binding site of the transcription factor HNF-3, but not the GRE, is the target sequence for the observed glucocorticoid/insulin antagonism. Therefore, HNF-3 or a liver-specific transcription factor with a similar binding specificity confers tissuespecific TAT gene expression (11) and mediates insulin repression of the glucocorticoid response.
DISCUSSION
Hormones play a crucial role in the perinatal activation of gluconeogenic enzymes. The onset of TAT and PEPCK expression around the time of birth coincides with a decrease in the insulin to glucagon molar ratio in response to postnatal hypoglycemia, resulting in a concomitant rise in the concentration of hepatic CAMP (2, 7). In the adult state, accurate modulation of enzyme activity depending on hormonal and dietary signals is a central feature of liver metabolism. Appropriate regulation requires that within one cell type, e.g. the hepatocyte, a hormone exerts positive and negative effects on distinct genes. Well studied examples are the processes of glycolysis and gluconeogenesis, which are inversely regulated by CAMP and insulin. Regulation involves alteration in the phosphorylation state of metabolic enzymes as well as alterations in the rate of mRNA synthesis (1).
Transcriptional regulation of TAT gene expression by CAMP has been characterized in detail (13,40), whereas the effects of insulin on TAT gene transcription are not very well understood (1). Our results clearly demonstrate that the CAMP-induced transcription of the endogenous TAT gene as well as stably transfected constructs with -1 l-or -3.6-kb 5'-flanking sequence is down-regulated by insulin in FTO-2B hepatoma cells. Due to the weak and variable effects, we cannot draw conclusions about insulin repression of basal transcription. However, induced transcription is significantly reduced by insulin. The CRE within the -3.6-kb enhancer is a key mediator of the CAMP/insulin antagonism. Specific IRS-binding proteins have not yet been identified, which suggests that insulin may act indirectly by interfering with the binding or activity of positively or negatively acting transcription factors (41). The critical role of the CRE suggests that insulin inhibits CAMPinduced transcription via a member of the ATF-l/CREB family. An elevated intracellular CAMP concentration leads to activation of the PKA pathway, which results in phosphorylation of CREB at Ser'33 (15, 16) . The effects of insulin on protein phosphorylation are complex and most likely involve multiple signal transduction pathways. Regulation of glycogen metabolism in mammalian skeletal muscle is an example of antagonism between insulin and adrenalin in which insulin-triggered events lead to dephosphorylation and activation of glycogen synthase (42). Further evidence that insulin causes an increase in phosphatase activity comes from cell culture studies using 3T3-Ll mouse adipocytes (43, 44). We, therefore, analyzed whether dephosphorylation of CREB at Ser'33 is a possible mechanism for the insulin-mediated repression of TAT gene transcription in FTO-2B hepatoma cells. Our study, however, shows that insulin does not reduce the CAMP-induced phosphorylation at Ser'33. We even observed a slight increase in phosphorylation, which might result from a protein kinase different from PKA, e.g. calcium/calmodulin-dependent protein kinase, that phosphorylates Ser'33 in CREB (45). The complex metabolic regulation by insulin involves phosphorylation cascades, which lead to an increased or decreased phosphorylation of cellular proteins (46). Studies of H4-IIE rat hepatoma cells and 3T3 mouse fibroblasts demonstrate, for example, the activation of CK-II in response to insulin (47, 48) . In that respect, it is of interest that within the kinase-inducible domain of CREB, potential target sites for several kinases, including CK-II, have been mapped (30) . Phosphorylation in addition to Ser'33 at distinct residues could result in a conformational change and, consequently, reduced transcriptional activity of CREB (29). As our data exclude opposing effects of CAMP and insulin at the PKA target site of CREB, the CAMP/ insulin antagonism may represent an example for the transduction of different signals by multisite phosphorylation of one protein.
The identification of the target protein for the insulin/ CAMP antagonism becomes more complicated due to the fact that two other CREB family members, ATF-1 (16) and the CAMP-responsive element modulator (49) also bind CREs and stimulate transcription.
Both proteins are potential heterodimerization partners of CREB and are regulated by PKA phosphorylation in response to CAMP (Ganss, R., unpublished observations). The presence of a second hormone-regulated protein in Western blot analysis supports the possibility that other family members in addition to CREB bind the TATCRE.
Using 3.6-kb 5'-flanking sequences of the TAT gene, including both hormone-dependent enhancers, we demonstrated that insulin counteracts dexamethasoneinduced transcription of the TAT gene. Moreover, dissection of the GRU showed that the HNF3-binding site adjacent to the GRE is the target sequence for insulin action. This sequence is known to restrict the activity of the glucocorticoid-inducible enhancer to liver cells (11). HNF-3 binding has been confirmed by in vitro assays; however, the binding of a related family member or a yet undefined liver-specific transcription factor in vivo cannot be excluded. There is evidence that phosphorylated forms of HNF-3 exist in liver nuclear extracts (50) that within the TAT GRU, insulin interferes not with the glucocorticoid receptor itself, but with a nearby DNA-binding factor. Interestingly, a second IRS has been postulated for the PEPCK gene between -271 and 69 bp (24) a promoter sequence which includes the CRE. With respect to the observation that a concatemerized PEPCK CRE confers insulin repression to a TKCAT reporter construct, we speculate that the CRE is the target for the CAMP/ insulin antagonism of both genes.
We concentrated our analysis of TAT gene regulation in response to insulin on the two inducible enhancers and demonstrated that the target sequences for inhibition by insulin are located within the CRE and an HNF-3-binding site. There is, however, evidence for additional target sites within the close promoter region (52). The key elements defined in this study are currently being tested in transgenic mice for their role in hormonal control and perinatal activation of the TAT gene.
MATERIALS AND METHODS

Cell Culture and Stable Transfections
The rat hepatoma cell line FTO-2B was cultured in a 1:l dilution of Dulbeccos's Modified Eagle's Medium and Ham's F-l 2 medium supplemented with 10% fetal calf serum, 100 U/ ml penicillin, 100 mg/ml streptomycin, and 10 mM HEPES (pH 7.4). Stable transfections were preformed by electroporation, as previously described (12). Two x 10' cells/ml were transfected with a 3:l molar ratio of the recombinant plasmid and a TKneo construct.
The selection medium contained 800 pg/ ml G418 (Gibco, Grand Island, NY 
